Cilastatina Sale Sodico + Imipenem Monoidrato + Relebactam shortage — IT supply status & alternatives

Cilastatina Sale Sodico + Imipenem Monoidrato + Relebactam

—

In supply · Australia

Recarbrio

In supply · 🇦🇺 Australia · short in🇮🇹 IT

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Cilastatina Sale Sodico + Imipenem Monoidrato + Relebactam
Brand names	Recarbrio
Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper
Controlled substance	No
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.